ArticleClinical case reports2023
A case report of insulinoma presenting with seizures and localized on endoscopic ultrasound.
Article in Clinical case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- Occult Insulinoma: A 19-Year Diagnostic Delay in a Patient With Recurrent Hypoglycemia.Cureus · 2026Article
- A case report of insulinoma presenting with seizures and localized on endoscopic ultrasound.Clinical case reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insulinomas are rare functioning neuroendocrine (NEN) tumors. Up to 10% of insulinomas are associated with multiple endocrine neoplasia 1 (MEN1). Most of the tumors present with symptomatic hypoglycemia. Several non-invasive and invasive techniques are used to localize the lesion. We present a case of insulinoma presenting with seizure episodes with negative results on non-invasive imaging diagnosed and localized with endoscopic ultrasound. A 36-year-old male was brought by ambulance to the emergency department with an episode of generalized tonic-clonic seizures. He had been previously healthy and did not have family history of neuro-endocrine tumors. At the time of the attack, the patient's blood glucose checked via point-of-care testing was 28.8 (70-99 mg/dL). He was given IV dextrose. Physical examination after the patient regained consciousness was completely unremarkable. Hypoglycemia workup revealed a normal morning cortisol level of 281 (138-689 nmol/L). Insulin level was 62.4 mcunit/ml (2.36-24.9), and c-peptide was 8.13 (1.1-4.4 ng/mL) consistent with hyperinsulinemia. Magnetic resonance cholangiopancreatography (MRCP), fluorine-18-l-dihydroxyphenylalanine whole-body positron emission tomography scan (NM 18F-DOPA whole-body PET scan), and gallium Ga 68 dodecanetetraacetic acid (Ga-68 DOTATATE) scan were normal and did not reveal any pancreatic lesion consistent with insulinoma. Due to high suspicion of insulinoma and negative non-invasive imaging, an endoscopic ultrasound (EUS) was performed, which showed a hypoechoic homogenous mass lesion sized 13 × 9 mm in the proximal body/neck of the pancreas. A fine needle biopsy (FNA) via EUS was performed. Histopathology showed a well-differentiated neuroendocrine tumor, consistent with Grade 1 insulinoma (T1N0M0). The patient underwent a distal pancreatectomy and splenectomy. In cases of high clinical and biochemical suspicion of insulinoma but negative non-invasive imaging, invasive modalities should be used to localize the culprit lesion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.